Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0IMAKZ
ADC Name
Mecbotamab vedotin
Synonyms
BA 3011; BA3011; CAB-AXL-ADC; CAB-Axl antibody-drug conjugates; HTBA-3011; HTBA3011; Mecbotamab Vedotin; Mecbotamab vedotin
   Click to Show/Hide
Organization
BioAtla, Inc.
Drug Status
Phase 1/2
Indication
In total 2 Indication(s)
Lung cancer
Phase 2
Clinical Trial
Solid tumor
Phase 2
Clinical Trial
Drug-to-Antibody Ratio
4
Structure
Antibody Name
Mecbotamab
  Antibody Info 
Antigen Name
Tyrosine-protein kinase receptor UFO (AXL)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random Cysteines
Combination Type
vedotin
Puchem SID
472420565 , 445594980 , 476000779
Drugbank ID
DB17442
ChEBI ID
CHEMBL5095312
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT04681131
Phase 2
A phase 2 study of BA3011 alone and in combination with PD-1 inhibitor in adult patients with metastatic non-small cell lung cancer (NSCLC) who had prior disease progression on a PD-1/L-1 inhibitor.
Undisclosed  NCT03425279
Phase 1
A phase 1/ 2 safety and efficacy dose escalation/dose expansion study of a CAB-AXL-ADC, alone and in combination with a PD-1 inhibitor in adult patients with advanced solid tumors (phase 1) and adult and adolescent patients with advanced, refractory sarcoma (phase 2).

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT04681131  Clinical Status Phase 2
Clinical Description A phase 2 study of BA3011 alone and in combination with PD-1 inhibitor in adult patients with metastatic non-small cell lung cancer (NSCLC) who had prior disease progression on a PD-1/L-1 inhibitor.
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT03425279  Clinical Status Phase 1
Clinical Description A phase 1/ 2 safety and efficacy dose escalation/dose expansion study of a CAB-AXL-ADC, alone and in combination with a PD-1 inhibitor in adult patients with advanced solid tumors (phase 1) and adult and adolescent patients with advanced, refractory sarcoma (phase 2).
References
Ref 1 A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor, NCT04681131
Ref 2 A Phase 1/ 2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-AXL-ADC, Alone and in Combination With a PD-1 Inhibitor in Adult Patients With Advanced Solid Tumors (Phase 1) and Adult and Adolescent Patients With Advanced, Refractory Sarcoma (Phase 2), NCT03425279